Compare SMWB & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMWB | MYGN |
|---|---|---|
| Founded | 2007 | 1991 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 551.0M | 444.2M |
| IPO Year | 2021 | 1996 |
| Metric | SMWB | MYGN |
|---|---|---|
| Price | $7.17 | $5.32 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 7 |
| Target Price | $4.00 | ★ $7.64 |
| AVG Volume (30 Days) | 1.0M | ★ 1.0M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $771,400,000.00 |
| Revenue This Year | $11.07 | $6.86 |
| Revenue Next Year | $11.17 | $5.45 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2.33 |
| 52 Week Low | $2.22 | $3.53 |
| 52 Week High | $10.75 | $8.59 |
| Indicator | SMWB | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 63.64 | 43.33 |
| Support Level | $6.91 | $4.24 |
| Resistance Level | $7.84 | $5.52 |
| Average True Range (ATR) | 0.53 | 0.29 |
| MACD | -0.08 | -0.13 |
| Stochastic Oscillator | 76.91 | 6.25 |
Similarweb Ltd provides digital data and analytics that power critical business decisions. The group recognizes revenue from subscriptions to the platform and other subscription products on a straight-line basis over the term of the contract subscription period beginning on the date access to the platform is granted, provided all other revenue recognition criteria have been met. It has geographic presence in Israel, the United States, the United Kingdom, Asia Pacific, Europe, and Other. The group generates the majority of its revenue from the United States.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.